Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;66(10):3681-3687.
doi: 10.1111/epi.18583. Epub 2025 Aug 5.

Evidence demands action: An invitation to share the burden of proof

Affiliations

Evidence demands action: An invitation to share the burden of proof

Danielle M Andrade et al. Epilepsia. 2025 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

D.M.A. received grant support from Dravet Syndrome Foundation; trial Support from Epygenix and Zogenix (UCB); And consultancy from Eisai, Biocodex, Stoke and Jazz; And serves on the medical advisory board for Dravet Syndrome Foundation. O.D. has equity and/or compensation from the following companies: Tilray, Tevard Biosciences, Regel Biosciences, Script Biosciences, Actio Biosciences, Empatica, Ajna Biosciences, Blackrock Neurotech, Emotiv, and Praxis Precision Therapeutics. He has received consulting fees or equity options from UCB Pharma and Ultragenyx. LIN UCB, PRAXIS, Abbott. J.A.A. is the President of the Dravet Syndrome Foundation Spain (DSF), and he and/or DSF have received grants and/or financial support from Jazz Pharma, UCB, Ovid Therapeutics, Encoded, Stoke, Takeda, Biocodex, Praxis, and StrideBio to help carry out some of DSF's founding activities or to provide consulting services. J.A.A. honoraria have always been donated directly or indirectly to the DSF. K.V. serves on São Paulo Research Foundation and receives support from Biocodex, Takeda, UCB, PRAXIS, Abbott, Prati‐Donaduzzi, ACHE, and Eurofarma. The remaining authors have no conflicts of interest. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

References

    1. Selvarajah A, Sabo A, Gorodetsky C, Marques PT, Chandran I, Thompson M, et al. Dravet syndrome: from neurodevelopmental to neurodegenerative disease? Epilepsia. 2025;66:1975–1987. 10.1111/epi.18329 - DOI - PMC - PubMed
    1. Sisodiya SM, Balestrini S, Berkovic SF, Bhatia KP, Clayton LM, Cross JH, et al. Is there really evidence for neurodegeneration in Dravet syndrome? Commentary on the publication by Selvarajah et al. Epilepsia. 2025. - PubMed
    1. Fasano A, Borlot F, Lang AE, Andrade DM. Antecollis and levodopa‐responsive parkinsonism are late features of Dravet syndrome. Neurology. 2014;82:2250–2251. - PMC - PubMed
    1. Kanatani M, Adachi T, Sakata R, Nishimura Y, Saito Y, Maegaki Y, et al. Dravet syndrome with parkinsonian symptoms and intact dopaminergic neurons: a case report. Brain Dev. 2021;43:486–489. - PubMed
    1. Deuel L, Collins AE, Maa EH, Barr JP, Kern DS. Dravet syndrome and parkinsonism: a case report investigating the dopaminergic system. Neurology. 2019;93:595–596. - PubMed

LinkOut - more resources